<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Harvard Law School Forum on Corporate Governance</title>
	<atom:link href="https://corpgov.law.harvard.edu/2014/06/02/communications-challenges-of-the-valeantpershing-square-bid-for-allergan/feed/" rel="self" type="application/rss+xml" />
	<link>https://corpgov.law.harvard.edu</link>
	<description>The leading online blog in the fields of corporate governance and financial regulation.</description>
	<lastBuildDate>Mon, 13 Apr 2026 18:42:00 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.5.8</generator>

<image>
	<url>https://corpgov.law.harvard.edu/wp-content/uploads/2024/02/cropped-photography-4-e1706898544564-1-32x32.png</url>
	<title>Communications Challenges of the Valeant/Pershing Square Bid for Allergan  &#8211; The Harvard Law School Forum on Corporate Governance</title>
	<link>https://corpgov.law.harvard.edu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Communications Challenges of the Valeant/Pershing Square Bid for Allergan</title>
		<link>https://corpgov.law.harvard.edu/2014/06/02/communications-challenges-of-the-valeantpershing-square-bid-for-allergan/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=communications-challenges-of-the-valeantpershing-square-bid-for-allergan</link>
		<comments>https://corpgov.law.harvard.edu/2014/06/02/communications-challenges-of-the-valeantpershing-square-bid-for-allergan/#comments</comments>
		<pubDate>Mon, 02 Jun 2014 16:14:41 +0000</pubDate>
<!-- 		<dc:creator><![CDATA[]]></dc:creator> -->
				<category><![CDATA[Mergers & Acquisitions]]></category>
		<category><![CDATA[Practitioner Publications]]></category>
		<category><![CDATA[Private Equity]]></category>
		<category><![CDATA[Hedge funds]]></category>
		<category><![CDATA[Inside information]]></category>
		<category><![CDATA[Pershing Square]]></category>
		<category><![CDATA[Shareholder activism]]></category>
		<category><![CDATA[Shareholder value]]></category>
		<category><![CDATA[Takeover premiums]]></category>
		<category><![CDATA[Takeovers]]></category>
		<category><![CDATA[Target firms]]></category>

		<guid isPermaLink="false">http://blogs.law.harvard.edu/corpgov/?p=63798?d=20141202125936EST</guid>
		<description><![CDATA[The bid by Valeant and Pershing Square to acquire Allergan has made a very big splash in the M&#38;A and corporate governance world. In brief, Pershing and Valeant have teamed up in a campaign to pressure Allergan to sell to Valeant in an unsolicited cash and stock deal. What distinguishes the Valeant/Pershing deal from a [&#8230;]]]></description>
				<content:encoded><![CDATA[<hgroup><em>Posted by Charles Nathan, RLM Finsbury, on Monday, June 2, 2014 </em><div class='e_n' style='background:#F8F8F8;padding:10px;margin-top:5px;margin-bottom:10px;text-indent:2.5em;'><strong style='margin-left:-2.5em;'>Editor's Note: </strong> <p style="margin:0; display:inline;"><a href="http://rlmfinsbury.com/en-us/our-people/profile/charles-nathan" target="_blank">Charles Nathan</a> is partner and head of the Corporate Governance Practice at RLM Finsbury. This post is based on an RLM Finsbury commentary by Mr. Nathan.</p>
</div></hgroup><p>The bid by Valeant and Pershing Square to acquire Allergan has made a very big splash in the M&amp;A and corporate governance world. In brief, Pershing and Valeant have teamed up in a campaign to pressure Allergan to sell to Valeant in an unsolicited cash and stock deal. What distinguishes the Valeant/Pershing deal from a conventional public bear hug (such as Pfizer’s recent effort to acquire AstraZeneca) is that, by pre-arrangement, Pershing Square acquired a 9.7% equity stake in Allergan immediately prior to the first public announcement of Valeant’s bear hug. This unusual deal structure is a first and, if successful, may pioneer a new paradigm for unsolicited takeovers of public companies.</p>
<p> <a href="https://corpgov.law.harvard.edu/2014/06/02/communications-challenges-of-the-valeantpershing-square-bid-for-allergan/#more-63798" class="more-link"><span aria-label="Continue reading Communications Challenges of the Valeant/Pershing Square Bid for Allergan">(more&hellip;)</span></a></p>
]]></content:encoded>
			<wfw:commentRss>https://corpgov.law.harvard.edu/2014/06/02/communications-challenges-of-the-valeantpershing-square-bid-for-allergan/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
	</channel>
</rss>
